|
Market Closed -
OTC Markets
15:50:25 2026-10-09 EDT
|
5-day change | 1st Jan Change | ||
| 0.0300 USD | +7.14% |
|
-18.92% | +15.38% |
| 05-18 | Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 11-17 | Adaptimmune Therapeutics plc Announces CEO Changes | CI |
| Market Cap | 7.95M 7.1M 6.61M 6.01M 11.35M 770M 11.39M 79.51M 31.15M 392M 29.86M 29.21M 1.26B | P/E 2024 |
-1.8x | P/E 2025 | 0.33x |
|---|---|---|---|---|---|
| Enterprise Value | -3.92M -3.5M -3.25M -2.96M -5.59M -379M -5.61M -39.17M -15.35M -193M -14.71M -14.39M -620M | EV / Sales 2024 |
0.34x | EV / Sales 2025 | -0.84x |
| Free-Float |
14.03% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +7.14% | ||
| 1 week | -18.92% | ||
| Current month | -21.05% | ||
| 1 month | +29.59% | ||
| 3 months | -9.09% | ||
| 6 months | +50.00% | ||
| Current year | +15.38% |
| 1 week | 0.02 |  | 0.04 |
| 1 month | 0 | | 0.04 |
| Current year | 0 | | 0.05 |
| 1 year | 0 | | 0.24 |
| 3 years | 0 | | 2.05 |
| 5 years | 0 | | 5.95 |
| 10 years | 0 | | 14.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Christopher Hill
CEO | Chief Executive Officer | 46 | 2025-11-13 |
Juli P. Miller
IRC | Investor Relations Contact | - | 2016-07-31 |
Phil Bassett
PRN | Corporate Officer/Principal | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Lawrence Alleva
CHM | Chairman | 76 | 2025-11-13 |
Garry Menzel
BRD | Director/Board Member | 61 | 2023-05-31 |
Christopher Hill
BRD | Director/Board Member | 46 | 2025-11-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/2/25 | Sell | Chief Financial Officer | 96,000 | 0.0060% | ||
| 8/28/25 | Sell | Compliance Officer | 207,000 | 0.0130% | ||
| 8/15/25 | NEA Management Co. LLC
| Sell | Company | 19,500,000 | 7.3571% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.14% | -18.92% | -83.78% | -95.59% | 7.95M | |
| +0.83% | +3.19% | +41.49% | +103.56% | 1,051B | |
| +1.93% | +2.11% | +37.08% | +65.09% | 630B | |
| +1.49% | +5.19% | +19.94% | +85.69% | 489B | |
| +2.26% | +0.90% | +69.32% | +40.53% | 359B | |
| +1.45% | +3.50% | +23.29% | +41.62% | 344B | |
| +1.17% | +2.37% | +13.47% | +33.64% | 272B | |
| +0.89% | +1.08% | -6.13% | +9.29% | 246B | |
| +1.82% | +2.94% | +42.99% | +52.95% | 224B | |
| +2.77% | +4.44% | +29.01% | +98.99% | 187B | |
| Average | +2.18% | +0.38% | +18.67% | +43.58% | 380.37B | |
| Weighted average by Cap. | +1.47% | +2.44% | +33.36% | +69.01% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 178M 159M 148M 135M 254M 17.23B 255M 1.78B 698M 8.78B 669M 654M 28.19B | 5.92M 5.29M 4.92M 4.48M 8.45M 573M 8.49M 59.24M 23.21M 292M 22.25M 21.76M 938M |
| Net income | -70.81M -63.24M -58.83M -53.51M -101M -6.85B -101M -708M -277M -3.49B -266M -260M -11.21B | 25.21M 22.51M 20.94M 19.05M 35.96M 2.44B 36.12M 252M 98.75M 1.24B 94.65M 92.58M 3.99B |
| Net Debt | -77.4M -69.12M -64.3M -58.49M -110M -7.49B -111M -774M -303M -3.82B -291M -284M -12.25B | -11.87M -10.6M -9.86M -8.97M -16.94M -1.15B -17.01M -119M -46.5M -586M -44.57M -43.6M -1.88B |
Employees
272
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-09 | US$0.0300 | +7.14% | 77,399 |
| 26-10-08 | US$0.0280 | +0.36% | 50,878 |
| 26-10-07 | US$0.0279 | -3.79% | 136,960 |
| 26-10-06 | US$0.0290 | -3.33% | 281,986 |
| 26-10-05 | US$0.0300 | -18.92% | 221,406 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ADAPY Stock
Select your edition
All financial news and data tailored to specific country editions
